Michael Ulz Analyst Performance

Michael Ulz is a stock analyst at Robert W. Baird, covering 27 publicly traded companies across a range of sectors. Over the past year, Michael Ulz has issued 20 stock ratings, including buy, hold, and sell recommendations. While full access to Michael Ulz's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Ulz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

72 Last 9 Years

Buy Recommendations

70.83% 51 Buy Ratings

Companies Covered

27 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	70.8%	51 ratings
Hold	27.8%	20 ratings
Sell	1.4%	1 ratings

Out of 72 total stock ratings issued by Michael Ulz at Robert W. Baird, the majority (70.8%) have been Buy recommendations, followed by 27.8% Hold and 1.4% Sell.

Best & Worst Calls

• Best Call

  0000.0%

  ISEE

  Jul 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  JNCE

  Mar 2018

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	27 companies

Michael Ulz, an analyst at Robert W. Baird, currently covers 27 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 27 companies	100.0%

Michael Ulz of Robert W. Baird specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	55.6%
MED - DRUGS 4 companies	14.8%
PHARMACEUTICAL PREPARATIONS 4 companies	14.8%
BIOTECHNOLOGY 2 companies	7.4%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 2 companies	7.4%

Michael Ulz's Ratings History at Robert W. Baird

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
KPTI Karyopharm Therapeutics	8/12/2025	Lower Price Target	$3.77	$25.00	Outperform	$0.00 00.00% ROI
RYTM Rhythm Pharmaceuticals	8/5/2025	Reiterated Rating	$88.57	$109.00	Overweight	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$392.24	$405.00	Equal Weight	$0.00 00.00% ROI
IONS Ionis Pharmaceuticals	7/31/2025	Upgrade	$43.37	$62.00	Overweight	$0.00 00.00% ROI
RYTM Rhythm Pharmaceuticals	7/9/2025	Set Price Target	$87.51	$95.00	Overweight	$0.00 00.00% ROI
KPTI Karyopharm Therapeutics	5/13/2025	Lower Price Target	$6.15	$42.00	Outperform	$0.00 00.00% ROI
SLN Silence Therapeutics	5/9/2025	Lower Price Target	$3.73	$25.00	Overweight	$0.00 00.00% ROI
VKTX Viking Therapeutics	4/24/2025	Lower Price Target	$25.52	$102.00	Overweight	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	4/11/2025	Lower Price Target	$231.02	$268.00	Equal Weight	$0.00 00.00% ROI
KYTX Kyverna Therapeutics	4/1/2025	Lower Price Target	$1.93	$20.00	Overweight	$0.00 00.00% ROI
CABA Cabaletta Bio	4/1/2025	Lower Price Target	$1.39	$22.00	Overweight	$0.00 00.00% ROI
AARD Aardvark Therapeutics	3/10/2025	Initiated Coverage	$10.13	$29.00	Overweight	$0.00 00.00% ROI
SLN Silence Therapeutics	3/5/2025	Lower Price Target	$4.38	$45.00	Overweight	$0.00 00.00% ROI
YMAB Y-mAbs Therapeutics	3/5/2025	Lower Price Target	$4.89	$7.00	Underweight	$0.00 00.00% ROI
KPTI Karyopharm Therapeutics	3/3/2025	Lower Price Target	$7.95	$54.00	Outperform	$0.00 00.00% ROI
IOVA Iovance Biotherapeutics	2/28/2025	Lower Price Target	$5.26	$20.00	Outperform	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	2/14/2025	Boost Price Target	$264.89	$284.00	Equal Weight	$0.00 00.00% ROI
THRD Third Harmonic Bio	2/12/2025	Downgrade	$3.25	$5.00	Equal Weight	$0.00 00.00% ROI
GUTS Fractyl Health	2/3/2025	Lower Price Target	$1.77	$10.00	Overweight	$0.00 00.00% ROI
AKRO Akero Therapeutics	1/28/2025	Boost Price Target	$52.07	$96.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.